Clinical Trial Update: Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma [NA]

View source ↗

Summary

Clinical trial update for Yttrium-90 glass microsphere radioembolization in hepatocellular carcinoma (TheraSphere) has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: University of California, San Francisco | Conditions: Hepatocellular Carcinoma | NA | Status: TERMINATED | Results posted: 2015-08-25